RenovoRx (RNXT) Stock Statistics & Valuation Metrics

RenovoRx has a market cap or net worth of $35.02M. The enterprise value is $36.04M.

RenovoRx has 36,645,885 shares outstanding. The number of shares has decreased by -2.65% in one year.

RenovoRx’s return on equity (ROE) is -1.97 and return on invested capital (ROIC) is -174.82%.

The current PE Ratio of RenovoRx is ―. RenovoRx’s PEG ratio is ―.

In the last 12 months, RenovoRx had revenue of 43.00K and earned -8.81M in profits. Earnings per share was -0.37.

In the last 12 months, operating cash flow was -1.04M and capital expenditures 0.00, giving a free cash flow of -1.04M billion.

RenovoRx pays an annual dividend of ―, resulting in a dividend yield of ―

RenovoRx upcoming earnings date is Nov 17, 2025, After Close (Confirmed).

RenovoRx as a current ratio of 4.10, with Debt / Equity ratio of 1.41%

In the past 12 months, RenovoRx has paid 0.00 in taxes.

RenovoRx EV to EBITDA ratio is -25.56, with an EV/FCF ratio of -30.69.

RenovoRx has $14.58M in cash and marketable securities with $283.00K in debt, giving a net cash position of -$14.30M billion.

Gross margin is 60.83%, with operating margin of -25511.63%, and net profit margin of -20497.67%.

The average price target for RenovoRx is $6.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy